64,045 Shares in Revolution Medicines, Inc. $RVMD Bought by General American Investors Co. Inc.

General American Investors Co. Inc. acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 64,045 shares of the company’s stock, valued at approximately $5,101,000.

Other institutional investors and hedge funds have also modified their holdings of the company. General Atlantic L.P. bought a new position in Revolution Medicines in the third quarter valued at about $115,556,000. Norges Bank bought a new position in Revolution Medicines in the fourth quarter valued at about $195,568,000. UBS Group AG raised its position in Revolution Medicines by 183.6% in the fourth quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock valued at $245,954,000 after purchasing an additional 1,998,972 shares during the last quarter. Nextech Invest Ltd. raised its position in Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after purchasing an additional 1,304,347 shares during the last quarter. Finally, Vestal Point Capital LP bought a new position in Revolution Medicines in the second quarter valued at about $44,148,000. 94.34% of the stock is currently owned by institutional investors.

Revolution Medicines Trading Up 3.1%

NASDAQ RVMD opened at $153.87 on Friday. The business has a 50 day simple moving average of $140.76 and a 200 day simple moving average of $110.42. Revolution Medicines, Inc. has a one year low of $34.00 and a one year high of $166.50. The stock has a market capitalization of $32.71 billion, a P/E ratio of -21.76 and a beta of 1.40. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.80 and a quick ratio of 6.80.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period last year, the business earned ($1.13) earnings per share. Research analysts expect that Revolution Medicines, Inc. will post -7.94 earnings per share for the current year.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 120,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the sale, the insider owned 276,698 shares of the company’s stock, valued at approximately $41,529,602.82. This trade represents a 30.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Xiaolin Wang sold 2,010 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $199,954.80. Following the completion of the sale, the insider directly owned 116,063 shares of the company’s stock, valued at $11,545,947.24. This trade represents a 1.70% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 148,592 shares of company stock valued at $20,855,132. Company insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on RVMD shares. Oppenheimer increased their target price on Revolution Medicines from $165.00 to $195.00 and gave the company an “outperform” rating in a research report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Tuesday, April 21st. Piper Sandler increased their target price on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Wedbush reiterated an “outperform” rating on shares of Revolution Medicines in a research report on Monday, June 1st. Finally, UBS Group started coverage on Revolution Medicines in a research report on Friday, February 27th. They issued a “buy” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $123.72.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.